^
    Back
    Association details:
    Biomarker:EGFR G465R
    Cancer:Colorectal Cancer
    Drug:futuximab/modotuximab (S95026) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Clin Cancer Res
    Title:

    The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

    Excerpt:
    ...a patient with a tumor harboring an EGFR mutation (G465R) following cetuximab therapy benefited from Sym004 therapy.
    DOI:
    10.1158/1078-0432.CCR-15-2400